An interventional study of Simvastatin in Statin-related Muscle Pain, Muscle Aches and Muscle Weakness, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-31.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Diagnostic
Roughly 5-10% of statin-treated patients report muscle pain, aches, weakness, cramps, stiffness, or "heaviness" - typically occurring symmetrically in the legs. For healthcare providers, the major diagnostic challenge is to unambiguously link these symptoms to statin use, especially since some patients can have normal serum creatine kinase (CK) levels despite demonstrable weakness and muscle biopsy proven statin-induced myopathy .
No well accepted, standardized, or Food and Drug Administration (FDA)-endorsed diagnostic method exists for statin-induced muscle injury. This lack of an objective diagnostic methodology blocks vertical advancement of the field.
The successful completion of this project will develop in vivo techniques that will provide insight into how statins affect muscle metabolism and help establish a methodology to objectively diagnose muscle injury due to statins. The development of an MRS technique will allow for in-vivo analyses and the data accumulated here will serve as preliminary data for futher extramural funding of studies with much larger sample sizes. Ultimately, this focus of research will lead to improved diagnosis and treatment of patients with statin-related muscle complaints, which is central to obtaining the cardiovascular risk reduction from lipid-lowering drugs.
The goal of the first study will be to generate hypothesis regarding the long-term effects of statin in muscles by studying 7T MRS findings in patients who are currently experiencing statin-related muscle complaints or who have a history of severe reactions to statins (i.e. rhabdomyolysis, anti-HMGCR-associated autoimmune myopathy, or CK elevation > 10 times the upper limit of normal). We anticipate enrolling roughly 5 such patients. The protocol involves a single visit for a blood draw and MRS of calf muscle. The data will be compared to historical controls provided by the Advanced Imaging Research Center.
Second, we will study the effect of short-term statin administration in 5 patients with a history of statin related muscle complaints and 5 controls with no statin related muscle complaints . Controls will be matched for age, weight, and body mass index. Patients will undergo a wash-out of lipid lowering drugs followed by a challenge with simvastatin 40 mg daily (similar to a statin withdrawal and rechallenge). We chose simvastatin since it is the most common statin that caused myopathy according to our preliminary data (as well as most other published reports). Each patient will have 5 visits. The screening visit will involve a review of inclusion/exclusion criteria, blood draw, questionnaire, and instructions to withhold all lipid lowering drugs until visit 1. Any patient with known antibodies to HMGCR will be excluded from the remainder of the study.
Visit 1 will occur 2 weeks after stopping all lipid lowering drugs. A minimum 2 week period off lipid lowering drugs is required to allow clearance of any medication from the systemic circulation. Patients will undergo MRS of the calf muscle and a blood draw. Patients will then start simvastatin 40 mg daily.
288 studies on the registry are indexed under Myalgia; 46 are open to participants now.
This study's enrollment of 8 is below the median of 44 across 245 interventional studies indexed under Myalgia.
Browse Myalgia studies →University of Texas Southwestern Medical Center is the lead sponsor of 1,009 studies on the registry; 201 are open to participants now.
Of its 138 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults age >18 yrs or \<80 yrs Patients reporting complaints of statin-associated muscle symptoms, aches, weakness, cramps, or stiffness of legs.
Exclusion Criteria:
Patients who drink large quantities of grapefruit juice (>1 quart daily)
Patients in substudy 1 will be identified by the PI from the clinic as individuals who are currently experiencing statin related muscle complaints or who have had severe reactions to statins in the past. There is going to be only one visit which will last for apprximately 3.5 hrs. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS.
Subjects with statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS. Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored
Drug: Simvastatin
Subjects with no statin related muscle complaints were enrolled in this arm and will have 3 visits. First visit is screening visit which will last for about 2 hrs and the next 2 visits will last for about 3.5 hrs. The screening visit will occur 2 weeks prior to visit 1. Subjects will have height, weight and vitals measured. They will be asked pain and and demographic questionnaire. They will have their blood draw and will undergo MRS. Some volunteers who do/do not regularly exercise or are/are not active in sports may be asked to exercise prior to the MRS. This exercise may be in the form of hand grasps, toe-raises, bicycling on a stationary bike or walking on a treadmill. Exercise will be limited to up to one hour, during which time the subject's vital signs and blood oxygenation will be monitored. During the scan, the subject's heart rate and respiratory rate may be monitored
Drug: Simvastatin
Simvastatin 40 mg daily.
Change in Pre- and Post-phosphocreatine Relaxation Time
Measure differences in pre- and post-phosphocreatine relaxation time in SAMS (Statin Associated Muscle Symptoms) patients on simvastatin compared to placebo.
Time frame: Baseline, 10 Weeks
| Milestone | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) |
|---|---|---|---|
| Started | 0 | 7 | 1 |
| Completed | 0 | 5 | 1 |
| Not completed | 0 | 2 | 0 |
Measure differences in pre- and post-phosphocreatine relaxation time in SAMS (Statin Associated Muscle Symptoms) patients on simvastatin compared to placebo.
| milliseconds | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) |
|---|---|---|---|
| Change in Pre- and Post-phosphocreatine Relaxation Time | — | 5.58 ± 1.6 | 5.083 ± 0 |
Collected over Data was collected over a period of 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| No Intervention: Arm 1 (Observational Arm) | — | — | — |
| Experimental: Arm 2 (Interventional Experimental Arm) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Experimental: Arm 3 (Interventional Control Arm) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Arm 1 is an observational study. No intervention involved. No data was collected for arm 1
| Age, Categorical(Participants) | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 2 | 1 | 3 |
| >=65 years | 0 | 5 | 0 | 5 |
| Sex: Female, Male(Participants) | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) | Total |
|---|---|---|---|---|
| Female | 0 | 4 | 0 | 4 |
| Male | 0 | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 0 | 2 | 0 | 2 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) | Total |
|---|---|---|---|---|
| Median | — | 31.2 ± 6.0 | 22 ± 0 | 26.6 ± 6 |
| Phospho Creatnine/ Adenosine Triphosphate (PCr/gATP)(ratio) | No Intervention: Arm 1 (Observational Arm) | Experimental: Arm 2 (Interventional Experimental Arm) | Experimental: Arm 3 (Interventional Control Arm) | Total |
|---|---|---|---|---|
| Mean | — | 4.765 ± 0.459 | 4.344 ± 0 | 12.85 ± 0.29 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
Ran from Mar 2016 to primary completion in Feb 2017, 11 months.
Results were first posted in Oct 2022, 5 years 8 months after primary completion.
Of 110 non-industry interventional studies with no phase under Myalgia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 11 months is above that.
Counting every sponsor, half of 119 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simvastatin
University of Texas Southwestern Medical Center →